Compare HURA & MMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HURA | MMTX |
|---|---|---|
| Founded | 2009 | 2025 |
| Country | United States | Taiwan |
| Employees | 19 | 2 |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 88.1M |
| IPO Year | N/A | N/A |
| Metric | HURA | MMTX |
|---|---|---|
| Price | $1.99 | $9.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 800.3K | 490.0 |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $139.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $9.89 |
| 52 Week High | $4.41 | $10.02 |
| Indicator | HURA | MMTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 58.53 |
| Support Level | $1.56 | $9.90 |
| Resistance Level | $2.20 | $10.02 |
| Average True Range (ATR) | 0.20 | 0.01 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 66.45 | 42.86 |
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Miluna Acquisition Corp is a blank check company.